RSI Chief Medical Officer, Dr. Donald R. Mattison, in collaboration with colleagues from the Institute for Safe Medication Practices and Wake Forest University, evaluated and compared the safety profiles of newer contraceptives using 43,324 adverse event case reports submitted to the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS), for the two years ending July 2017. The presentation on Saturday, March 10, 2018 in San Diego described the strong safety profiles of the newer contraceptives, as well as issues of concern.
For more details see the presentation poster here.
More RSI News
Value of information analysis framework
In its 2007 report on Toxicity Testing in the 21st Century: A Vision and a Strategy, the US National Research Council (NRC) highlighted need for more rapid…
Principles of risk decision-making
RSI investigators propose fundamental principles of risk decision-making, and explore their application in a range of real-world risk decision-making contexts. These ten principles will provide valuable guidance on addressing current and future risk issues facing civil societies worldwide.
Risk of Myocarditis and Pericarditis
Using data from the US Centers for Disease Control (CDC) Vaccine Adverse Event Reporting System, RSI investigators collaborated on a study showing increased risks of…
Quinolones and risk of retinal detachment
Following previous work on the potential risk of acute liver failure associated with quinolone antibiotics, RSI investigators, Mohamed Taher, Franco Momoli, Donald Mattison and Daniel…